BrainsWay (NASDAQ:BWAY - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Investors that wish to listen to the company's conference call can do so using this link.
BrainsWay (NASDAQ:BWAY - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.04 EPS for the quarter. The business had revenue of $10.01 million during the quarter, compared to the consensus estimate of $9.40 million. BrainsWay had a net margin of 1.67% and a return on equity of 1.45%. During the same period in the previous year, the firm posted ($0.05) earnings per share. On average, analysts expect BrainsWay to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
BrainsWay Trading Up 0.1 %
Shares of NASDAQ BWAY traded up $0.01 during midday trading on Tuesday, reaching $10.33. 50,986 shares of the stock were exchanged, compared to its average volume of 95,005. The company has a market capitalization of $172.30 million, a P/E ratio of 206.44 and a beta of 1.25. BrainsWay has a 52-week low of $3.78 and a 52-week high of $10.61. The stock has a 50 day moving average price of $8.85 and a 200-day moving average price of $7.20.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on BWAY shares. Northland Securities lifted their price target on shares of BrainsWay from $11.00 to $12.50 and gave the stock an "outperform" rating in a report on Thursday, October 3rd. HC Wainwright reissued a "buy" rating and issued a $16.00 target price on shares of BrainsWay in a research report on Monday, October 21st.
View Our Latest Stock Analysis on BWAY
About BrainsWay
(
Get Free Report)
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Featured Articles
Before you consider BrainsWay, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BrainsWay wasn't on the list.
While BrainsWay currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
